Navigation Links
Red wine compound increases anti-tumor effect of rapamycin
Date:2/14/2011

Monday, February 14, 2011 Cleveland Researchers from Cleveland Clinic's Lerner Research Institute have discovered that resveratrol a compound found in red wine when combined with rapamycin can have a tumor-suppressing effect on breast cancer cells that are resistant to rapamycin alone.

The research recently published in Cancer Letters also indicates that the PTEN tumor-suppressing gene contributes to resveratrol's anti-tumor effects in this treatment combination.

Charis Eng, MD, Ph.D., Chair of the Genomic Medicine Institute of Cleveland Clinic's Lerner Research Institute, led her team to study the effect of combining resveratrol, a chemopreventive drug found in many natural compounds, with rapamycin on breast cancer cells. The research demonstrates an additive effect between these two drugs on breast cancer cell signaling and growth.

"Rapamycin has been used in clinical trials as a cancer treatment. Unfortunately, after a while, the cancer cells develop resistance to rapamycin," Eng said. "Our findings show that resveratrol seems to mitigate rapamycin-induced drug resistance in breast cancers, at least in the laboratory. If these observations hold true in the clinic setting, then enjoying a glass of red wine or eating a bowl of boiled peanuts which has a higher resveratrol content than red wine before rapamycin treatment for cancer might be a prudent approach."

Rapamycin, an immunosuppressant drug used to prevent rejection in organ transplantation, has been considered for the use of anti-tumor activity against breast cancer. Resveratrol is a type of polyphenol that is found in the skin of red grapes and is a constituent of red wine, and has been considered for multiple uses regarding cellular therapies.

Despite the potential for tumor suppression, rapamycin's efficacy with respect to growth inhibition differs markedly among various breast cancer cell lines. The effect of resveratrol and rapamycin, alone and in combination, on cell growth of three human breast cancer cell lines was assessed. Rapamycin, resveratrol, and combinations of these agents inhibited cell growth in a dose-dependent manner. In all three cell lines tested, the presence of low concentrations of resveratrol and rapamycin was sufficient to induce 50 percent growth inhibition. Although relatively early, these observations may suggest resveratrol as a powerful integrative medicine adjunct to traditional chemotherapy.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Related medicine news :

1. Compound shows promise against intractable heart failure
2. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
3. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
4. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
5. Researchers find compound effective in destroying antibiotic-resistant biofilms
6. Compound enhances cancer-killing properties of agent in trials
7. Concentration, timing and interactions are key when it comes to dietary compounds
8. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
9. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
10. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
11. New investigational compound targets pancreatic cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... the country today, as organizations, advocates, and individuals join together to increase recognition ... access to ultimately save lives. , “Today we mark a nationwide movement to ...
(Date:2/22/2017)... ... February 22, 2017 , ... Becker’s Spine Review, the ... featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a “Spine Surgeon to Know.” ... neurosurgeons in Michigan performing minimally invasive back surgery that often results in less ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael J. ... media platform connecting healthcare technology professionals and other key stakeholders with an array ... publication starting on March 1, announced Michael J. Hennessy, Jr., president of MJH ...
(Date:2/22/2017)... ... 2017 , ... Super-Sod will attend the Athens Home Show with a brand ... shift from Super-Sod’s simple Athens Home Show booth of 2016, this year’s exhibit space ... manager Chris Roquemore constructed furniture from recycled pallet wood at the Super-Sod farm in ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... who suffer from combat-related PTSD. , Established in 1977, our organization was at ... challenges of military returning to civilian life were evident and served as the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Colo. , Feb. 22, 2017  Aytu BioScience, ... global commercialization of novel products in the field of ... team to up to 42 account managers from 35 ... The sales force expansion is being ... prescriptions and revenues, an indication of increasing acceptance of ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 According ... (Spectroscopy, Chromatography), Measurement (On-Line, In-Line, At-Line), Products and Services (Analyzers, Probes & ... to 2021", published by MarketsandMarkets, the global market is poised to reach ... a CAGR of 13.3% from 2016 to 2021. ... ...
(Date:2/22/2017)... Feb. 22, 2017  CVS Pharmacy is the first ... partially hydrogenated oils (PHO), the primary source of artificial ... store brands food products. The retailer now offers over ... from artificial trans fats. This comes a year and a ... of June 2018 for processed foods to be reformulated ...
Breaking Medicine Technology: